Management Report on Square Pharmaceuticals Ltd

Management is the process of directing resources, organizing in order to effectively maintain and achieve business, organizational goals and creative problem solving. Directing resources means people, materials, finances and information. “Those who become managers and successful leader are the people who can best transmit their views, ideas, and enthusiasm to others” (Baldwin & Bommer, 2008, pg. 47). The goal of management is to accomplish the business mission and objective. To be a successful manager, you need skills in decision making, financial analysis, interpersonal relationships, and communication as well as the ability to apply those skills in a context of restraints, opportunities, and options. The following management analysis paper

Economic: Globalization of the pharmaceutical industry is an exciting opportunity to have research and development done at cheaper prices in other countries. However, this could be a double edged sword for companies because it is easy for other countries, such as India, to produce generic versions of the drug in bulk.

Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its

1. Pricing: Many Asian and African countries are poor and cannot afford the costly medicines. The Pharmaceutical firms spend vast amounts on R&D in creating and marketing drugs, thus charging high prices enables for cost of capital recovery and profit generation.

This course explores the rich field of management in theory and practice, and as both a science and an art. Students learn to apply management concepts to current workplace issues. Other topics include increasing competitive forces, expectations for successful performance of employees and organizations, and achieving desired business goals.

Although the vision of the organization represents the future, the mission allows for current goals (Renz, 2010). Then you include the strategies which is usually updated and worked on every 3-5

They can make billons by selling generic medications to developing countries abroad, from the film it states there will be a 20% increase in evolving markets by 2020. These generic medications are marketing fast because of the price for the medicine. (www.utube.com, 2014)”.

Joseph Dumit announces how pharmaceutical organizations are exploiting us shoppers, control with showcasing procedures and making it so we return for more solution. These brings up the issue do pharmaceuticals have our best enthusiasm to make us more beneficial or are they just in it for the cash. Dumit states that in 2011 pharmaceuticals made about $880 billion dollars and is relied upon to grow 5% consistently later on (18). Dumit thinks something is wrong with these organizations and takes a gander at the ceaseless development in medications, conclusion, expenses and weakness, he adopted the strategy to take after cash and following associations between the benefits of organizations and ailment extension (10).

In this paper I will be responding to an article by Richard Anderson, business reporter for the BBC NEWS, titled “Pharmaceutical Industry Gets High On Fat Profits.” In Anderson’s article, the most interesting topics are how some drugs can really help and even save lives, how pharmaceutical companies have been accused of some corruptions, and how there is controversy surrounding profiting of drug companies. Overall, I learned a great deal from this article.

In this paper I will discuss Pharmaceutical Research and Manufacturers of America (PhRMA) I will talk about its purpose, scope, design, application, and how they affect the healthcare economy.

Does the source of data either internal or external shed light on the objectives? [11].

A company like Teva Pharmaceuticals is subject to all of the factors of the external environment given the nature of its business and global expansion. Pharmaceuticals is an industry where high profits can be achieved, but it is also an extremely challenging business when one considers all of the political/legal aspects involving government regulation and patents. Every country has strict regulation and testing requirements for drugs that affect companies differently depending on their position in the market. Originally, innovative pharmaceutical companies had to obtain patent protection and FDA approval but this would translate to years of protection from the generic competition. Once the

High Gross Margin: Since the company produces unique drugs, it can price them high in the market as long as no competitor produces a similar drug. Hence a pharmaceutical company can command a substantial gross margin like the one showed here.

Upon completion of this course, students will be able to: 1. To develop an understanding of management functions and

GSK is the 2nd largest pharmaceutical firm in the world, and the largest in the UK by sales and profits, it is responsible for 7% of the worlds pharmaceutical market, and has its stocks listed both in UK and US (O 'Rourke, 2002). The origin of the so called blockbuster model, is partly linked with Glaxo (as it was previously known). In the early 80’s, then Glaxo brought to light their first blockbuster drug, Zantac, which was an anti-ulcer drug, which was very similar to the a pre existing drug Tagamet (first ever blockbuster) sold by Smith Kline & French, their completion at the time (MONTALBAN and SAKINÇ, 2011). The introduction of this drug, brought about an increasing sales force in the US, the company soon became dependent on the drug, because it represented a large part of their profit. In 2002, 8 blockbusters of GSK contributed to $14.240 million sales revenue, taking up 53% of its total ethical sales (Froud et al 2006). However, due to the nature of the pharmaceutical industry, the patent began to expire, in other to avoid the patent cliff, Glaxo merged with Wellcome in 1995, which ensured a growing number of sales force, and with Beecham in 2000 (Froud et al., 2006) this merger, boosted the confidence of investors, by growing the business inorganically. For Big Pharma, this block buster model is very profitable, because with the high cost of R&D, the drugs are able to generate ample profit, to cover the sunk costs